Schizophrenia Research
Volume 76, Issue 2 , Pages 247-265 , 15 July 2005

Manual for the Extrapyramidal Symptom Rating Scale (ESRS)

  • Guy Chouinard

      Affiliations

    • Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, and Department of Psychiatry, McGill University, 1025 Pine Ave. West, Montreal, QC, Canada, H3A 1A1
    • Fernand-Seguin Research Centre, Louis-H. Lafontaine Hospital, Montreal and Department of Psychiatry University of Montreal, Montreal, QC, Canada, H1N 3M5
    • Corresponding Author InformationCorresponding author. Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, and Department of Psychiatry, McGill University, 1025 Pine Ave. West, Montreal, QC, Canada, H3A 1A1. Tel.: +1 514 843 1672; fax: +1 514 982 6620.
    • ,
  • Howard C. Margolese

      Affiliations

    • Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, and Department of Psychiatry, McGill University, 1025 Pine Ave. West, Montreal, QC, Canada, H3A 1A1

Received 16 September 2004 ,Revised 18 February 2005 ,Accepted 21 February 2005.

References 

  1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4th text rev. (DSM-IV-TR) Washington, DC: American Psychiatric Press; 2000;
  2. Annable L, Chouinard G, Ross-Chouinard A. Factor analysis of the extrapyramidal symptom rating scale. In: Collegium Internationale Neuro–Psychopharmacologicum (C. I. N. P. ) 18th Congress, Book of Abstracts Suppl. 1, part B (No. P-55-274). 1992;p. 376B
  3. Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur. Neuropsychopharmacol. 2004;14:87–92
  4. Chouinard G. A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation. Acta Psychiatr. Scand., Suppl. 1990;358:111–119
  5. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J. Clin. Psychopharmacol. 1995;15:36S–44S
  6. Chouinard G. New nomenclature for drug-induced movement disorders including tardive dyskinesia. J. Clin. Psychiatry. 2004;65(Suppl. 9):9–15
  7. Chouinard G, Annable L. Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit. Am. J. Psychiatry. 1976;133:850–853
  8. Chouinard G, Annable L. Pimozide in the treatment of newly admitted schizophrenic patients. Psychopharmacology (Berl.). 1982;76:13–19
  9. Chouinard G, Annable L, Serrano M, Charette R. A controlled study of a dopa decarboxylase inhibitor (benserazide) in the treatment of schizophrenic patients. Int. Pharmacopsychiatry. 1977;12:1–8
  10. Chouinard G, Annable L, Young SN, Sourkes TL. Tryptophan-benserazide in the treatment of schizophrenia. Commun. Psychopharmacol. 1978;2:21–31
  11. Chouinard G, Annable L, Ross-Chouinard A, Kropsky ML. Ethopropazine and benztropine in neuroleptic-induced Parkinsonism. J. Clin. Psychiatry. 1979;40:147–152
  12. Chouinard G, Annable L, Ross-Chouinard A, Nestoros JN. Factors related to tardive dyskinesia. Am. J. Psychiatry. 1979;136:79–82
  13. Chouinard G, de Montigny C, Annable L. Tardive dyskinesia and antiParkinsonian medication. Am. J. Psychiatry. 1979;136:228–229
  14. Chouinard G, Ross-Chouinard A, Annable L, Jones B. The extrapyramidal symptom rating scale. Can. J. Neurol. Sci. 1980;7(3):233
  15. Chouinard G, Annable L, Ross-Chouinard A. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect. Am. J. Psychiatry. 1982;139:312–318
  16. Chouinard G, Young SN, Annable L. Antimanic effect of clonazepam. Biol. Psychiatry. 1983;18:451–466
  17. Chouinard G, Ross-Chouinard A, Gauthier S, Annable L, Mercier P. An extrapyramidal rating scale for idiopathic and neuroleptic-induced Parkinsonism and dyskinesia. In: Collegium Internationale Neuro-Psychopharmacologicum (C. I. N P.) 14th Congress, Book of Abstracts. 1984;p. 16
  18. Chouinard G, Young SN, Annable L. A controlled clinical trial of l-tryptophan in acute mania. Biol. Psychiatry. 1985;20:546–557
  19. Chouinard G, Annable L, Mercier P, Turnier L. Long-term effects of l-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms. Psychopharmacol. Bull. 1987;23:221–226
  20. Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J. Clin. Psychopharmacol. 1988;8:21S–26S
  21. Chouinard G, Annable L, Campbell W. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. J. Clin. Psychopharmacol. 1989;9:247–253
  22. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 1993;13:25–40
  23. Chouinard G, Margolese HC, Alphs L, Larach-Walters V, Beauclair L, Anand R. Relationship between baseline extrapyramidal symptoms and suicidality in schizophrenic subjects included in the InterSePT trial. Biol. Psychiatry. 2002;51:20S–21S
  24. Chouinard G, Bhanji NH, Light M, Margolese HC. Patient characteristics, symptom severity, and movement disorders in patients with schizophrenia and schizoaffective disorder. Biol. Psychiatry. 2003;53:21S
  25. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets. In: American College of Neuropsychopharmacology Annual Meeting. December 9–13, Waikoloa HI USA. 2001;
  26. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am. J. Psychiatry. 2004;161:414–425
  27. de Montigny C, Chouinard G, Annable L. Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study. Psychopharmacology (Berl). 1979;65:219–223
  28. Dion Y, Annable L, Sandor P, Chouinard G. Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 2002;22:31–39
  29. Fahn S, Elton RL. Unified Parkinson's disease rating scale. In:  Fahn S,  Marsden CD,  Goldstein M,  Calne DB editor. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Healthcare Information; 1987;p. 153–163
  30. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J. Clin. Psychiatry. 2003;64:1250–1257
  31. Gharabawi, G., Lasser, R., Bossic, C., Turkoz, L., Rodriguez, S., Lonchena, C., Chouinard, G., in press. AIMS and ESRS: cross-scale comparison to define simplified criteria for tardive dyskinesia. Int. J. Neuropsychopharmacol. 7, S165.
  32. Guy, E. Abnormal Involuntary Movement Scale. 1976. Rockville, MD, National Institute of Mental Health, U.S. Department of Health and Human Services. ECDEU Assessment Manual for Psychopharmacology: revised 1976.
  33. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–442
  34. Hoehn, M.M., Yahr, M.D., 2001. Parkinsonism: onset, progression, and mortality. 1967. Neurology 57, S11-S26.
  35. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am. J. Psychiatry. 2000;157:1150–1155
  36. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry. 2003;160:1125–1132
  37. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry. 1994;151:825–835
  38. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J. Clin. Psychiatry. 1997;58:538–546
  39. Margolese HC, Chouinard G, Walters-Larach V, Beauclair L. Relationship between antipsychotic-induced akathisia and tardive dyskinesia and suicidality in schizophrenia: impact of clozapine and olanzapine. Acta Psychiatr. Belg. 2001;101:128–144
  40. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry. 2003;60:82–91
  41. Moller HJ, Muller H, Borison RL, Schooler NR, Chouinard G. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a re-evaluation of the North American risperidone study. Eur. Arch. Psychiatry Clin. Neurosci. 1995;245:45–49
  42. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp. Community Psychiatry. 1988;39:1172–1177
  43. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch. Gen. Psychiatry. 2000;57:249–258
  44. Rifkin A, Quitkin F, Klein DF. Akinisia: a poorly recognized drug-induced extrapyramidal behavioral disorder. Arch. of Gen. Psychiatry. 1975;32:672–674
  45. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry. 1982;39:486–487
  46. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand., Suppl. 1970;212:11–19

PII: S0920-9964(05)00078-2

doi: 10.1016/j.schres.2005.02.013

Schizophrenia Research
Volume 76, Issue 2 , Pages 247-265 , 15 July 2005

Article Tools